In a filing, Crinetics Pharmaceuticals Inc revealed its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported $86021.0 on Mar 19 ’25. In the deal valued at $34.20 per share,2,515 shares were sold. As a result of this transaction, Pizzuti Dana now holds 72,233 shares worth roughly $2.39 million.
Then, Knight Jeff E. sold 7,162 shares, generating $244,964 in total proceeds. Upon selling the shares at $34.20, the Chief Operating Officer now owns 87,491 shares.
Before that, Betz Stephen F. sold 5,770 shares. Crinetics Pharmaceuticals Inc shares valued at $197,353 were divested by the Chief Scientific Officer at a price of $34.20 per share. As a result of the transaction, Betz Stephen F. now holds 108,588 shares, worth roughly $3.59 million.
Stifel initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published on March 25, 2025; the price target was $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Wolfe Research began covering CRNX with “Peer perform” recommendation on February 04, 2025. Jefferies revised its rating on January 22, 2025. It rated CRNX as “a Buy” which previously was an “a Hold”.
Price Performance Review of CRNX
On Tuesday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock jump 2.48% to $33.08. Over the last five days, the stock has gained 3.05%. Crinetics Pharmaceuticals Inc shares have fallen nearly -35.30% since the year began. Nevertheless, the stocks have fallen -27.84% over the past one year.
How much short interest is there in Crinetics Pharmaceuticals Inc?
A steep rise in short interest was recorded in Crinetics Pharmaceuticals Inc stocks on 2025-05-15, growing by 0.53 million shares to a total of 10.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 9.63 million shares. There was a rise of 5.24%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 06, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $68 price target.
